1
|
Dutta B, Loo S, Kam A, Tam JP. Plant-derived cell-penetrating microprotein α-astratide aM1 targets Akt signaling and alleviates insulin resistance. Cell Mol Life Sci 2023; 80:293. [PMID: 37715850 PMCID: PMC10505102 DOI: 10.1007/s00018-023-04937-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2023] [Revised: 08/23/2023] [Accepted: 08/24/2023] [Indexed: 09/18/2023]
Abstract
Insulin-resistant diabetes is a common metabolic disease with serious complications. Treatments directly addressing the underlying molecular mechanisms involving insulin resistance would be desirable. Our laboratory recently identified a proteolytic-resistant cystine-dense microprotein from huáng qí (Astragalus membranaceus) called α-astratide aM1, which shares high sequence homology to leginsulins. Here we show that aM1 is a cell-penetrating insulin mimetic, enters cells by endocytosis, and activates the PI3K/Akt signaling pathway independent of the insulin receptor leading to translocation of glucose transporter GLUT4 to the cell surface to promote glucose uptake. We also showed that aM1 alters gene expression, suppresses lipid synthesis and uptake, and inhibits intracellular lipid accumulation in myotubes and adipocytes. By reducing intracellular lipid accumulation and preventing lipid-induced, PKCθ-mediated degradation of IRS1/2, aM1 restores glucose uptake to overcome insulin resistance. These findings highlight the potential of aM1 as a lead for developing orally bioavailable insulin mimetics to expand options for treating diabetes.
Collapse
Affiliation(s)
- Bamaprasad Dutta
- School of Biological Sciences, Nanyang Technological University, 60 Nanyang Drive, Singapore, 637551, Singapore
| | - Shining Loo
- School of Biological Sciences, Nanyang Technological University, 60 Nanyang Drive, Singapore, 637551, Singapore
- Academy of Pharmacy, Xi'an Jiaotong-Liverpool University, Suzhou, 215123, China
| | - Antony Kam
- School of Biological Sciences, Nanyang Technological University, 60 Nanyang Drive, Singapore, 637551, Singapore
- Department of Biological Sciences, Xi'an Jiaotong-Liverpool University, Suzhou, 215123, China
| | - James P Tam
- School of Biological Sciences, Nanyang Technological University, 60 Nanyang Drive, Singapore, 637551, Singapore.
| |
Collapse
|
2
|
Gorai B, Vashisth H. Structural models of viral insulin-like peptides and their analogs. Proteins 2023; 91:62-73. [PMID: 35962629 PMCID: PMC9772067 DOI: 10.1002/prot.26410] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2022] [Revised: 07/21/2022] [Accepted: 08/09/2022] [Indexed: 12/24/2022]
Abstract
The insulin receptor (IR), the insulin-like growth factor-1 receptor (IGF1R), and the insulin/IGF1 hybrid receptors (hybR) are homologous transmembrane receptors. The peptide ligands, insulin and IGF1, exhibit significant structural homology and can bind to each receptor via site-1 and site-2 residues with distinct affinities. The variants of the Iridoviridae virus family show capability in expressing single-chain insulin/IGF1 like proteins, termed viral insulin-like peptides (VILPs), which can stimulate receptors from the insulin family. The sequences of VILPs lacking the central C-domain (dcVILPs) are known, but their structures in unbound and receptor-bound states have not been resolved to date. We report all-atom structural models of three dcVILPs (dcGIV, dcSGIV, and dcLCDV1) and their complexes with the receptors (μIR, μIGF1R, and μhybR), and probed the peptide/receptor interactions in each system using all-atom molecular dynamics (MD) simulations. Based on the nonbonded interaction energies computed between each residue of peptides (insulin and dcVILPs) and the receptors, we provide details on residues establishing significant interactions. The observed site-1 insulin/μIR interactions are consistent with previous experimental studies, and a residue-level comparison of interactions of peptides (insulin and dcVILPs) with the receptors revealed that, due to sequence differences, dcVILPs also establish some interactions distinct from those between insulin and IR. We also designed insulin analogs and report enhanced interactions between some analogs and the receptors.
Collapse
Affiliation(s)
- Biswajit Gorai
- Department of Chemical Engineering, University of New Hampshire, Durham, NH 03824, USA
| | - Harish Vashisth
- Department of Chemical Engineering, University of New Hampshire, Durham, NH 03824, USA
| |
Collapse
|
3
|
Sen S, Ali R, Onkar A, Ganesh S, Verma S. Strategies for interference of insulin fibrillogenesis: challenges and advances. Chembiochem 2022; 23:e202100678. [PMID: 35025120 DOI: 10.1002/cbic.202100678] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2021] [Revised: 01/11/2022] [Indexed: 11/10/2022]
Abstract
The discovery of insulin came up with very high hopes for diabetic patients. In the year 2021, the world celebrated the 100 th anniversary of the discovery of this vital hormone. However, external use of insulin is highly affected by its aggregating tendency that occurs during its manufacturing, transportation, and improper handling which ultimately leads its pharmaceutically and biologically ineffective form. In this review, we aim to discuss the various approaches used for decelerating insulin aggregation which results in the enhancement of its overall structural stability and usage. The approaches that are discussed are broadly classified as either a measure through excipient additions or by intrinsic modifications in the insulin native structure.
Collapse
Affiliation(s)
- Shantanu Sen
- Indian Institute of Technology Kanpur, Chemistry, INDIA
| | - Rafat Ali
- Indian Institute of Technology Kanpur, Chemistry, Room No 131 Lab No2, CESE department IIT Kanpur, 208016, Kanpur, INDIA
| | - Akanksha Onkar
- Indian Institute of Technology Kanpur, Biological Sciences and Bioengineering, INDIA
| | - Subramaniam Ganesh
- Indian Institute of Technology Kanpur, Biological Sciences and Bioengineering, INDIA
| | - Sandeep Verma
- Indian Institute of Technology-Kanpur, Department of Chemistry, IIT-Kanpur, 208016, Kanpur, INDIA
| |
Collapse
|
4
|
A novel method for the chaperone aided and efficient production of human proinsulin in the prokaryotic system. J Biotechnol 2022; 346:35-46. [DOI: 10.1016/j.jbiotec.2022.01.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2021] [Revised: 12/27/2021] [Accepted: 01/13/2022] [Indexed: 02/07/2023]
|
5
|
Cell free protein synthesis versus yeast expression - A comparison using insulin as a model protein. Protein Expr Purif 2021; 186:105910. [PMID: 34089870 DOI: 10.1016/j.pep.2021.105910] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2021] [Revised: 05/17/2021] [Accepted: 05/18/2021] [Indexed: 11/20/2022]
Abstract
Expression of recombinant proteins traditionally require a cellular system to transcribe and translate foreign DNA to a desired protein. The process requires special knowledge of the specific cellular metabolism in use and is often time consuming and labour intensive. A cell free expression system provides an opportunity to express recombinant proteins without consideration of the living cell. Instead, a cell free system relies on either a cellular lysate or recombinant proteins to carry out protein synthesis, increasing overall production speed and ease of handling. The one-pot cell free setup is commonly known as an in vitro transcription/translation reaction (IVTT). Here we focused on a PURE (Protein synthesis Using Recombinant Elements) IVTT system based on recombinant proteins from Escherichia coli. We evaluated the cell free system's ability to express functional insulin analogues compared to Saccharomyces cerevisiae, a well-established system for large scale production of recombinant human insulin and insulin analogues. Significantly, it was found that correct insulin expression and folding was governed by the inherent properties of the primary amino acids sequence of insulin, whereas the eukaryotic features of the expression system apparently play a minor role. The IVTT system successfully produced insulin analogues identical in structure and with similar insulin receptor affinity to those produced by yeast. In conclusion we demonstrate that the PURE IVTT system is highly suited for expressing soluble molecules with higher order features and multiple disulphide bridges.
Collapse
|
6
|
Faust C, Ochs C, Korn M, Werner U, Jung J, Dittrich W, Schiebler W, Schauder R, Rao E, Langer T. Production of a novel heterodimeric two-chain insulin-Fc fusion protein. Protein Eng Des Sel 2020; 33:5959880. [PMID: 33159202 DOI: 10.1093/protein/gzaa026] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2020] [Revised: 10/02/2020] [Accepted: 10/05/2020] [Indexed: 01/12/2023] Open
Abstract
Insulin is a peptide hormone produced by the pancreas. The physiological role of insulin is the regulation of glucose metabolism. Under certain pathological conditions the insulin levels can be reduced leading to the metabolic disorder diabetes mellitus (DM). For type 1 DM and, dependent on the disease progression for type 2 DM, insulin substitution becomes indispensable. To relieve insulin substitution therapy for patients, novel insulin analogs with pharmacokinetic and pharmacodynamic profiles aiming for long-lasting or fast-acting insulins have been developed. The next step in the evolution of novel insulins should be insulin analogs with a time action profile beyond 1-2 days, preferable up to 1 week. Nowadays, insulin is produced in a recombinant manner. This approach facilitates the design and production of further insulin-analogs or insulin-fusion proteins. The usage of the Fc-domain from immunoglobulin as a fusion partner for therapeutic proteins and peptides is widely used to extend their plasma half-life. Insulin consists of two chains, the A- and B-chain, which are connected by two disulfide-bridges. To produce a novel kind of Fc-fusion protein we have fused the A-chain as well as the B-chain to Fc-fragments containing either 'knob' or 'hole' mutations. The 'knob-into-hole' technique is frequently used to force heterodimerization of the Fc-domain. Using this approach, we were able to produce different variants of two-chain-insulin-Fc-protein (tcI-Fc-protein) variants. The tcI-Fc-fusion variants retained activity as shown in in vitro assays. Finally, prolonged blood glucose lowering activity was demonstrated in normoglycemic rats. Overall, we describe here the production of novel insulin-Fc-fusion proteins with prolonged times of action.
Collapse
Affiliation(s)
- Christine Faust
- Sanofi-Aventis Deutschland GmbH, R&D Biologics Research, Industriepark Höchst, 65926 Frankfurt am Main, Germany
| | - Christian Ochs
- Sanofi-Aventis Deutschland GmbH, R&D Biologics Research, Industriepark Höchst, 65926 Frankfurt am Main, Germany.,Provadis School of International Management and Technology AG, Industriepark Höchst, 65926 Frankfurt am Main, Germany
| | - Marcus Korn
- Sanofi-Aventis Deutschland GmbH, R&D TA Diabetes, Industriepark Höchst, 65926 Frankfurt am Main, Germany
| | - Ulrich Werner
- Sanofi-Aventis Deutschland GmbH, R&D TA Diabetes, Industriepark Höchst, 65926 Frankfurt am Main, Germany
| | - Jennifer Jung
- Sanofi-Aventis Deutschland GmbH, R&D Biologics Research, Industriepark Höchst, 65926 Frankfurt am Main, Germany
| | - Werner Dittrich
- Sanofi-Aventis Deutschland GmbH, R&D Biologics Research, Industriepark Höchst, 65926 Frankfurt am Main, Germany
| | - Werner Schiebler
- Provadis School of International Management and Technology AG, Industriepark Höchst, 65926 Frankfurt am Main, Germany
| | - Rolf Schauder
- Provadis School of International Management and Technology AG, Industriepark Höchst, 65926 Frankfurt am Main, Germany
| | - Ercole Rao
- Sanofi-Aventis Deutschland GmbH, R&D Biologics Research, Industriepark Höchst, 65926 Frankfurt am Main, Germany
| | - Thomas Langer
- Sanofi-Aventis Deutschland GmbH, R&D Biologics Research, Industriepark Höchst, 65926 Frankfurt am Main, Germany
| |
Collapse
|